Skip to content

Cannabis for addiction: all studies

Page 4 of 6: studies 31 to 40 of 59, newest first. Back to the cannabis for addiction overview

Research

Attenuated Psychotic Symptoms in Adolescents With Chronic Cannabis and MDMA Use

Frontiers in Psychiatry January 21, 2022 Melina Wiedmann, Sören Kuitunen-Paul, Lukas A Basedow et al. 5 citations

ObjectivesBoth substance use, on the one hand, and the first signs of psychosis, on the other, commonly begin in adolescence. Adolescents with substance use disorder (SUD) frequently show recreational use of cannabis and 3,4-methylenedioxymethamphetamine (MDMA). When attenuated psychotic symptoms (APS) occur during the course of SUD, they are commonly attributed to the cannabis use, neglecting...

Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation

Current Topics in Behavioral Neurosciences 2022 Matthew W. Johnson 31 citations

This manuscript reviews research suggesting that classic psychedelics (5-HT2A receptor agonists) are effective in treating addictions including tobacco use disorder. I review historical research from the 1950s to 1970s suggesting that classic psychedelics are associated with addiction recovery across pharmacologically distinct drugs of addiction. I then review anthropological reports about...

Differences between users' and addiction medicine experts' harm and benefit assessments of licit and illicit psychoactive drugs: Input for psychoeducation and legalization/restriction debates.

Frontiers in Psychiatry 2022 Udo Bonnet, Michael Specka, Ann-Kristin Kanti et al. 4 citations

There is a lack of benefit/harm assessments of illicit and licit psychoactive substances performed by substance-dependent users in comparison to addiction medicine experts. We extended the analyses of substance harm/benefit assessments of German addiction medicine experts (N = 101), in parts reported recently in this journal [doi.org/10.3389/fpsyt.2020.59219], by the perspectives of...

Substance-Induced Psychoses: An Updated Literature Review

Frontiers in Psychiatry December 23, 2021 A. Fiorentini, Filippo Cantù, Camilla Crisanti et al. 123 citations

Background: On the current psychopharmacological panorama, the variety of substances able to provoke an episode of acute psychosis is rapidly increasing. Such psychotic episodes are classified according to the major category of symptoms: positive, negative, or cognitive psychotic episodes. On one hand, the abuse of methamphetamines, cannabis, and cocaine plays a big role in increasing the...

Policy in focus: Is psilocybin the next cannabis?

Canadian Medical Association Journal November 14, 2021 Greg Basky 7 citations

Research interest in the therapeutic use of psilocybin, or "magic mushrooms," is growing alongside a "wild west" of dispensaries in Canada and the United States. The past decade has seen a revival of research exploring the clinical use of psychedelics in treating depression, addiction,

Psilocybin: Next to treat depression, OCD and nicotine addiction

Alcoholism & Drug Abuse Weekly September 24, 2021 Alison Knopf

First it was the plant, cannabis. How could this be made into a saleable profit‐making commodity when it grows in the ground? Witness the marijuana (a chemical from the plant) industry, which lobbied to make sure laws in states that legalized it banned people from growing more than a few plants.

Cannabis Use and Psychosis – Modern Views on the Problem. Narrative Synthesis

Medicina 2021 A. J. Kolgashkin, П. Н. Николаев, E. J. Tetenova et al. 1 citation

Cannabis continues to be the most widely used drug worldwide. Recently, there has been two trends in the field: a liberalization of cannabis-related legislation in a number of countries, as well as an increase in the content of the psychoactive component in cannabis plant – tetrahydrocannabinol. The review covers a topic that has been little studied in Russian addiction science – cannabis use...

The good, the bad, and the intoxicated

2021 Natasha Leigh Mason

Cannabis is the most commonly used illicit drug and is known to alter state of consciousness and impair neurocognitive function. However, the mechanisms underlying these effects have yet to be fully elucidated. Rodent studies suggest that 9-tetrahydrocannabinol (THC) activates dopaminergic neurons in the limbic system, subsequently enhancing dopamine, which is implicated in the rewarding...

Individual and combined effects of Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) on striato-cortical connectivity in the human brain

bioRxiv (Cold Spring Harbor Laboratory) November 21, 2020 Matthew B. Wall, Tom P. Freeman, Chandni Hindocha et al. 4 citations preprint

Abstract Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are two major constituents of cannabis with contrasting mechanisms of action. THC is the major psychoactive, addiction-promoting, and psychotomimetic compound, while CBD may have somewhat opposite effects. The brain effects of these drugs alone and in combination are poorly understood. In particular the striatum is implicated in the...

MDMA Use by Paris Medical Students: Prevalence and Characteristics

Substance Use & Misuse October 24, 2020 Balthazar Bazin, David Duroy, Michel Lejoyeux 27 citations

3,4-Methylenedioxy-N-methylamphetamine (MDMA) is increasing being used by youth in Europe and in France, but characteristics of its use are unknown. Objectives: The aim was to characterize MDMA use in a sample of French medical students. Methods: Cross-sectional study of Paris VII medical students (N = 592) with an online self-reporting questionnaire. Results: 592 students completed the online...